Literature DB >> 26836918

Pleural Effusions at First ED Encounter Predict Worse Clinical Outcomes in Patients With Pneumonia.

Nathan C Dean1, Paula P Griffith2, Jeffrey S Sorensen3, Lindsay McCauley4, Barbara E Jones5, Y C Gary Lee6.   

Abstract

BACKGROUND: Pleural effusions are present in 15% to 44% of hospitalized patients with pneumonia. It is unknown whether effusions at first presentation to the ED influence outcomes or should be managed differently.
METHODS: We studied patients in seven hospital EDs with International Statistical Classification of Disease and Health Related Problems-Version 9 codes for pneumonia, or empyema, sepsis, or respiratory failure with secondary pneumonia. Patients with no confirmatory findings on chest imaging were excluded. Pleural effusions were identified with the use of radiographic imaging.
RESULTS: Over 24 months, 4,771 of 458,837 adult ED patients fulfilled entry criteria. Among the 690 (14.5%) patients with pleural effusions, their median age was 68 years, and 46% were male. Patients with higher Elixhauser comorbidity scores (OR, 1.13 [95% CI, 1.09-1.18]; P < .001), brain natriuretic peptide levels (OR, 1.20 [95% CI, 1.12-1.28]; P < .001), bilirubin levels (OR, 1.07 [95% CI, 1.00-1.15]; P = .04), and age (OR, 1.15 [95% CI, 1.09-1.21]; P < .001) were more likely to have parapneumonic effusions. In patients without effusion, electronic version of CURB-65 (confusion, uremia, respiratory rate, BP, age ≥ 65 years accurately predicted mortality (4.7% predicted vs 5.0% actual). However, eCURB underestimated mortality in those with effusions (predicted 7.0% vs actual 14.0%; P < .001). Patients with effusions were more likely to be admitted (77% vs 57%; P < .001) and had a longer hospital stay (median, 2.8 vs 1.3 days; P < .001). After severity adjustment, the likelihood of 30-day mortality was greater among patients with effusions (OR, 2.6 [CI, 2.0-3.5]; P < .001), and hospital stay was disproportionately longer (coefficient, 0.22 [CI, 0.14-0.29]; P < .001).
CONCLUSIONS: Patients with pneumonia and pleural effusions at ED presentation in this study were more likely to die, be admitted, and had longer hospital stays. Why parapneumonic effusions are associated with adverse outcomes, and whether different management of these patients might improve outcome, needs urgent investigation.
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  brain natriuretic peptide; emergency medicine; pleural effusion; pneumonia

Mesh:

Year:  2016        PMID: 26836918      PMCID: PMC6026265          DOI: 10.1016/j.chest.2015.12.027

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

1.  Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data.

Authors:  Danielle A Southern; Hude Quan; William A Ghali
Journal:  Med Care       Date:  2004-04       Impact factor: 2.983

2.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

Review 3.  Generalized linear mixed models: a practical guide for ecology and evolution.

Authors:  Benjamin M Bolker; Mollie E Brooks; Connie J Clark; Shane W Geange; John R Poulsen; M Henry H Stevens; Jada-Simone S White
Journal:  Trends Ecol Evol       Date:  2009-03       Impact factor: 17.712

4.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

5.  Comorbidity measures for use with administrative data.

Authors:  A Elixhauser; C Steiner; D R Harris; R M Coffey
Journal:  Med Care       Date:  1998-01       Impact factor: 2.983

6.  Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group.

Authors:  B J Marston; J F Plouffe; T M File; B A Hackman; S J Salstrom; H B Lipman; M S Kolczak; R F Breiman
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

7.  Predictive factors, microbiology and outcome of patients with parapneumonic effusion.

Authors:  M Falguera; J Carratalà; S Bielsa; C García-Vidal; A Ruiz-González; I Chica; F Gudiol; J M Porcel
Journal:  Eur Respir J       Date:  2011-05-12       Impact factor: 16.671

8.  A comparison of Charlson and Elixhauser comorbidity measures to predict colorectal cancer survival using administrative health data.

Authors:  Jessica R Lieffers; Vickie E Baracos; Marcy Winget; Konrad Fassbender
Journal:  Cancer       Date:  2010-12-22       Impact factor: 6.860

Review 9.  Pneumonia and empyema: causal, casual or unknown.

Authors:  Lindsay McCauley; Nathan Dean
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

10.  Validating hospital admission criteria for decision support in pneumonia.

Authors:  Barbara E Jones; Jason P Jones; Caroline G Vines; Nathan C Dean
Journal:  BMC Pulm Med       Date:  2014-09-22       Impact factor: 3.317

View more
  12 in total

1.  Streptococcus Gordonii Empyema: A Case Report and Review of Empyema.

Authors:  Amanda M Krantz; Felicia Ratnaraj; Manasa Velagapudi; Mridula Krishnan; Nagarjuna R Gujjula; Pamela A Foral; Laurel Preheim
Journal:  Cureus       Date:  2017-04-12

2.  Risk Stratification in Patients with Complicated Parapneumonic Effusions and Empyema Using the RAPID Score.

Authors:  Sunkaru Touray; Rahul N Sood; Daniel Lindstrom; Jonathan Holdorf; Sumera Ahmad; Daniel B Knox; Andres F Sosa
Journal:  Lung       Date:  2018-08-11       Impact factor: 2.584

Review 3.  Stage-directed therapy of pleural empyema.

Authors:  Martin Reichert; Matthias Hecker; Biruta Witte; Johannes Bodner; Winfried Padberg; Markus A Weigand; Andreas Hecker
Journal:  Langenbecks Arch Surg       Date:  2016-11-04       Impact factor: 3.445

Review 4.  Infectious pleural effusion status and treatment progress.

Authors:  Wei Yang; Bo Zhang; Ze-Ming Zhang
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

5.  Pleural effusion as an indicator for the poor prognosis of COVID-19 patients.

Authors:  Xiao-Shan Wei; Xu Wang; Lin-Lin Ye; Yi-Ran Niu; Wen-Bei Peng; Zi-Hao Wang; Jian-Chu Zhang; Qiong Zhou
Journal:  Int J Clin Pract       Date:  2021-03-16       Impact factor: 3.149

6.  Thoracic Empyema as Rare Complication of an Appendicular Mass: A Case Study and Review of the Literature.

Authors:  George Vasquez-Rios; Lesly Calixto-Aguilar; Richard Pajuelo; Wilder Alarcon
Journal:  Case Rep Pediatr       Date:  2018-05-15

7.  Diagnosis of Parapneumonia Pleural Effusion with Serum and Pleural Fluid Cell-Free DNA.

Authors:  Chih-Min Su; Chia-Te Kung; Sheng-Yuan Hsiao; Nai-Wen Tsai; Yun-Ru Lai; Chih-Cheng Huang; Hung-Chen Wang; Wei-Che Lin; Ben-Chung Cheng; Yu-Jih Su; Cheng-Hsien Lu
Journal:  Biomed Res Int       Date:  2019-03-04       Impact factor: 3.411

8.  Nicotinamide phosphoribosyltransferase as a biomarker for the diagnosis of infectious pleural effusions.

Authors:  Jing Huang; Lun Guo; Hong-Wei Kang; Dan Lv; Wei Lin; Chao-Fen Li; Xue-Qin Huang; Qun-Li Ding
Journal:  Sci Rep       Date:  2021-10-26       Impact factor: 4.379

9.  Diagnosis of infectious pleural effusion using predictive models based on pleural fluid biomarkers.

Authors:  Lucía Ferreiro; Óscar Lado-Baleato; Juan Suárez-Antelo; María Elena Toubes; María Esther San José; Adriana Lama; Nuria Rodríguez-Núñez; José Manuel Álvarez-Dobaño; Francisco J González-Barcala; Jorge Ricoy; Francisco Gude; Luis Valdés
Journal:  Ann Thorac Med       Date:  2019 Oct-Dec       Impact factor: 2.219

10.  Steroid therapy and outcome of parapneumonic pleural effusions (STOPPE): Study protocol for a multicenter, double-blinded, placebo-controlled randomized clinical trial.

Authors:  Deirdre B Fitzgerald; Grant W Waterer; Catherine A Read; Edward T Fysh; Ranjan Shrestha; Christopher Stanley; Sanjeevan Muruganandan; Norris S H Lan; Natalia D Popowicz; Carolyn J Peddle-McIntyre; Najib M Rahman; Seng Khee Gan; Kevin Murray; Yun Chor Gary Lee
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.